Traumatic Injury with MCC DRG Reimbursement & Medicare

Summary & Overview

Traumatic Injury with MCC: Inpatient Reimbursement Overview

DRG 913 encompasses severe traumatic injury admissions with a Major Complication or Comorbidity that drive higher clinical complexity and resource needs. Correct assignment affects inpatient reimbursement because Medicare Severity Diagnosis-Related Group payment is adjusted upward to account for increased expected costs associated with major complications or comorbidities.

Traumatic Injury with Major Complication or ComorbidityDRG Traumatic Injury with MCCDRG 913Diagnosis-Related GroupInpatient ReimbursementMedicareTrauma SurgeryCritical CareEmergency MedicineOrthopedic Trauma

DRG 913 Overview

DRG 913 covers inpatient stays for patients admitted with severe traumatic injuries accompanied by a Major Complication or Comorbidity, reflecting high clinical complexity and resource use. This Diagnosis-Related Group groups cases where trauma care requires intensive interventions, extended monitoring, or multiple specialties. It matters for Medicare payment because classification into this DRG typically yields higher reimbursement to reflect greater expected costs and longer lengths of stay. Accurate coding and documentation of the Major Complication or Comorbidity drive appropriate assignment to this DRG.

National Payment Rates

Across payers, negotiated rates for DRG 913 range from about $8.4K (BCBS minimum) up to $53K (Anthem maximum), with mean payer-specific averages spanning roughly $13K to $27K. The widest spread between payer minima and maxima appears in the Anthem and Cigna data, showing substantial variability across commercial payers. See the table and chart below for payer-level detail and distributional context.

Mean Rates by Payer — National — DRG 913

The CMS 2023 data represent national Medicare fee-for-service inpatient payments as reported in the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($15.5k), average submitted covered charges ($75.2k), average Medicare payment amount ($12.9k), and total discharges (809).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

DRG 913 in Alaska shows a payer rate range from about $7.5K up to $70K across observed payers, with most payers clustering near $24K–$25K while Cigna stands out at a substantially higher mean and median. The divergence is most pronounced at the upper end where Cigna’s p75 and max push the state distribution above typical national medians. See the table and chart below for the payer-level detail and distribution.

Key Insights for Alaska

Highest payer: Cigna (median $39K; mean $41K), notably above other local payers.
Lowest payer: Blue Cross Blue Shield (BCBS) and Anthem (median $25K; mean $24K) at the low end of the state range.
Meaningful deviation: Cigna’s mean and upper quartile (mean $41K; p75 $66K) sit well above national medians, creating a wider state spread compared with national benchmarks.

Clinical Trials

Acute hemostasis and resuscitation trials: randomized or pragmatic studies testing different strategies for early hemorrhage control, blood product ratios, and damage-control resuscitation protocols in severely injured adults with life‑threatening blunt or penetrating trauma and multiple comorbidities. These trials enroll patients in the emergency department or operating room, often within hours of injury, to evaluate immediate mortality, transfusion requirements, and complications such as coagulopathy and organ failure. Findings are directly relevant to hospitals and payers because they inform resource use in the highest‑acuity phase of care, influence length of stay in intensive care units, and affect short‑term mortality and complication costs for DRG 913 cases.
Comparative effectiveness studies of surgical vs nonoperative management and timing of definitive fracture or organ repair: cohort studies and randomized trials comparing early definitive fixation or operative repair versus staged or nonoperative approaches in traumatically injured patients who also have major comorbid conditions (for example, older adults with osteoporosis, cardiovascular disease, or chronic anticoagulation). These studies focus on functional outcomes, complication rates (infection, thromboembolism), readmission, and cumulative inpatient days across the index hospitalization and early post‑discharge period. Results help clinicians and payers understand tradeoffs between upfront operative resource use and downstream costs from complications or prolonged rehabilitation, guiding care pathways and reimbursement risk adjustment for complex trauma patients.
Post‑discharge outcomes and rehabilitation trials: longitudinal studies and randomized trials of inpatient-to-community transitions, early intensive rehabilitation, and secondary prevention interventions for survivors of traumatic injury with major complications (for example, patients discharged with disability after traumatic brain injury, spinal cord injury, or multisystem trauma). These trials measure long‑term functional recovery, quality of life, return to work, and utilization of home health and readmissions over months to years. For providers and payers, this research is crucial because improvements in post‑acute care and coordinated discharge planning can reduce costly readmissions, long‑term institutionalization, and overall total cost of care for patients classified under DRG 913.

Related Codes

915-ALLERGIC-REACTIONS-WITH-MCC

Allergic Reactions with MCC: Inpatient Reimbursement Overview

914-TRAUMATIC-INJURY-WITHOUT-MCC

Traumatic Injury without MCC: Inpatient Reimbursement Overview

905-SKIN-GRAFTS-FOR-INJURIES-WITHOUT-CC-MCC

Skin Grafts for Injuries without CC/MCC: Inpatient Reimbursement Overview

922-OTHER-INJURY-POISONING-AND-TOXIC-EFFECT-DIAGNOSES-WITH-MCC

Other Injury, Poisoning and Toxic Effect Diagnoses with MCC: Inpatient Reimbursement Overview

923-OTHER-INJURY-POISONING-AND-TOXIC-EFFECT-DIAGNOSES-WITHOUT-MCC

Other Injury, Poisoning and Toxic Effect Diagnoses without MCC: Inpatient Reimbursement Overview

907-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-MCC

Other O.R. Procedures for Injuries with MCC: Inpatient Reimbursement Overview

917-POISONING-AND-TOXIC-EFFECTS-OF-DRUGS-WITH-MCC

Poisoning and Toxic Effects of Drugs with MCC: Inpatient Reimbursement Overview

921-COMPLICATIONS-OF-TREATMENT-WITHOUT-CC-MCC

Complications of Treatment without CC/MCC: Inpatient Reimbursement Overview

908-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-CC

Other O.R. Procedures for Injuries with CC: Inpatient Reimbursement Overview

904-SKIN-GRAFTS-FOR-INJURIES-WITH-CC-MCC

Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 19

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$15K	$75K	$13K	810

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 913

Key Insights for Alaska

Highest payer: Cigna (median $39K; mean $41K), notably above other local payers.
Lowest payer: Blue Cross Blue Shield (BCBS) and Anthem (median $25K; mean $24K) at the low end of the state range.
Meaningful deviation: Cigna’s mean and upper quartile (mean $41K; p75 $66K) sit well above national medians, creating a wider state spread compared with national benchmarks.

Clinical Trials

Acute hemostasis and resuscitation trials: randomized or pragmatic studies testing different strategies for early hemorrhage control, blood product ratios, and damage-control resuscitation protocols in severely injured adults with life‑threatening blunt or penetrating trauma and multiple comorbidities. These trials enroll patients in the emergency department or operating room, often within hours of injury, to evaluate immediate mortality, transfusion requirements, and complications such as coagulopathy and organ failure. Findings are directly relevant to hospitals and payers because they inform resource use in the highest‑acuity phase of care, influence length of stay in intensive care units, and affect short‑term mortality and complication costs for DRG 913 cases.
Comparative effectiveness studies of surgical vs nonoperative management and timing of definitive fracture or organ repair: cohort studies and randomized trials comparing early definitive fixation or operative repair versus staged or nonoperative approaches in traumatically injured patients who also have major comorbid conditions (for example, older adults with osteoporosis, cardiovascular disease, or chronic anticoagulation). These studies focus on functional outcomes, complication rates (infection, thromboembolism), readmission, and cumulative inpatient days across the index hospitalization and early post‑discharge period. Results help clinicians and payers understand tradeoffs between upfront operative resource use and downstream costs from complications or prolonged rehabilitation, guiding care pathways and reimbursement risk adjustment for complex trauma patients.
Post‑discharge outcomes and rehabilitation trials: longitudinal studies and randomized trials of inpatient-to-community transitions, early intensive rehabilitation, and secondary prevention interventions for survivors of traumatic injury with major complications (for example, patients discharged with disability after traumatic brain injury, spinal cord injury, or multisystem trauma). These trials measure long‑term functional recovery, quality of life, return to work, and utilization of home health and readmissions over months to years. For providers and payers, this research is crucial because improvements in post‑acute care and coordinated discharge planning can reduce costly readmissions, long‑term institutionalization, and overall total cost of care for patients classified under DRG 913.